Zol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zol

What is Zol? Defining the Anti-Infective Entity

The medicinal product Zol, which is based on the active ingredient Metronidazole, is a highly specialized, prescription-only agent targeting specific microbial illnesses. It is classified as an anti-infective agent and synthetic compound that addresses infections caused by organisms thriving in low-oxygen environments.


Quick Facts: Zol (Metronidazole) Identity

Property Description
Active ingredient Metronidazole
Origin Synthetic compound (Nitroimidazole derivative)
Pharmacological Class Nitroimidazole Antibiotic and Antiprotozoal Agent
Key Dosage Forms Tablets, Solution for Infusion, Topical Gels/Creams
Primary Action Bactericidal (Kills susceptible organisms)

Defining Classification and Mechanism

The core identity of Zol lies in its classification as a nitroimidazole antibiotic and a potent antiprotozoal agent. This designation applies to its use against certain anaerobic bacteria and protozoal organisms. Metronidazole is a single-ingredient product, and its mechanism is highly selective: it remains inert until it enters the low-oxygen environment of the target pathogen, where it becomes chemically activated to cause DNA damage. This targeted action is intended for eliminating pathogens that standard oxygen-dependent antibiotics often cannot reach.


Available Preparations and General Purpose

Zol is supplied in various dosage forms to ensure its active ingredient reaches the site of infection effectively, facilitating both systemic action (internal body-wide use) and local action (site-specific use). Metronidazole is utilized for treating infections caused by susceptible anaerobes, with delivery methods tailored to the clinical need. The availability of tablets, solution for infusion, and topical preparations allows for specific delivery routes; the solution for infusion is used in hospital settings for severe systemic infections, while the topical preparations address localized skin or gynecological conditions.

Regulatory References

  1. NIH Metronidazole Monograph

What side effects are possible with Zol?

Zolpidem, a common treatment for insomnia, can cause various side effects. It is critical to take this medication only when you are ready to go to bed and have a full 7 to 8 hours for sleep, as it can cause next-day drowsiness, dizziness, and impaired coordination. Do not drive or operate machinery until you know how the medication affects you and your ability to be fully alert.

Common Side Effects

Side effects that occur more frequently include headache, drowsiness, dizziness, diarrhea, and a stuffy or runny nose.

Serious Warnings and Rare Effects

Zolpidem carries a risk of serious and potentially life-threatening side effects, including complex sleep behaviors (CSBs) like sleepwalking, sleep-driving, making and eating food, or engaging in other activities while not fully awake, often with no memory of the event. A Boxed Warning highlights the risk of serious injury or death from these behaviors. Stop taking Zolpidem and seek immediate medical attention if you experience CSBs.

Other serious effects may include:

  • Allergic reactions (anaphylaxis and angioedema), which can cause swelling of the tongue, face, or throat and difficulty breathing.
  • Worsening of depression or the emergence of suicidal thoughts or actions.
  • Abnormal thoughts and behavior changes, such as agitation, hallucinations, or a feeling of detachment.

Safety Considerations

Zolpidem can be habit-forming, and its use should generally be limited to short periods. Abruptly stopping the medication after extended use may lead to withdrawal symptoms or rebound insomnia (difficulty sleeping that is worse than before treatment). The risk of side effects, including next-day impairment and falls, may be increased in older adults and with concurrent use of alcohol or other central nervous system (CNS) depressants. Discuss your medical history, particularly liver or breathing problems, mental illness, or history of substance use disorder, with your healthcare provider before starting Zolpidem.

Overdose and Emergency Response

Documented Overdose Manifestations and Actions

The official regulatory documentation for Zol (Metronidazole) describes specific manifestations and required actions in cases of acute overdose. Overdose has been reported following single oral doses up to 15 grams and is primarily associated with gastrointestinal and neurological symptoms. Documented manifestations include nausea, vomiting, and ataxia (a lack of muscle coordination).

The most severe documented outcomes involve neurotoxicity. These include serious, life-threatening effects such as convulsive seizures, peripheral neuropathy (e.g., numbness or paresthesia), and encephalopathy. The appearance of any abnormal neurological signs mandates the prompt discontinuation of the drug.

Emergency Management and Monitoring

Immediate medical help must be sought if symptoms of severe neurotoxicity, collapse, trouble breathing, or unconsciousness occur. The regulatory labels confirm that no specific antidote is known for Zol overdose. Management, therefore, consists of providing symptomatic and supportive therapy.

Hemodialysis is documented as a procedural option that can effectively remove a significant portion of the administered dose and accumulated metabolites. Monitoring for adverse events is recommended, particularly in populations at higher risk for accumulation, such as those with severe hepatic impairment or end-stage renal disease (ESRD), due to potentially impaired drug clearance.

Therapeutic Uses of Zol

Zol's primary therapeutic value lies in its focused ability to target specific organisms that thrive in low-oxygen environments, and may support the easing of associated serious and uncomfortable symptoms they cause across several body systems. This medication is used across conditions involving acute or disruptive bacterial and parasitic infections.


Treatment of Infections and Symptom Patterns

This medication is applied in clinical settings that involve acute or unstable symptom patterns of serious infections deep within the body, such as septicemia or intra-abdominal abscesses, as well as common infections like Bacterial Vaginosis, Trichomoniasis, and certain forms of Amebiasis. It helps address symptom clusters that may appear suddenly and create noticeable functional strain, including intense fever, profound, localized pain, and bothersome vaginal discharge or diarrhea. The drug is relevant for managing symptoms that interfere with daily comfort.

“Zol provides supportive therapeutic benefit by supporting a more manageable clinical course during challenging, acute phases of illness.”

Zol is also commonly used for managing symptoms related to inflammatory or irritative states, such as the redness and lesions of Rosacea on the skin, and is applied during surgical procedures to help mitigate the risk of postoperative infection. This support assists with maintaining functional stability when symptoms become more noticeable.

Quick Fact: Relief for Anaerobic Symptoms
Primary Focus: Supportive relief for systemic and localized discomfort driven by anaerobic bacteria and protozoal parasites.
Context: Relevant in contexts involving conditions marked by internal abscesses, pelvic infections, or gastrointestinal distress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Zol

Regulatory authorities strictly define the population eligible to use Zol (Metronidazole). The medicine is contraindicated and must not be used by patients with a known prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Absolute non-eligibility also applies to patients with Cockayne Syndrome due to the risk of severe, irreversible hepatotoxicity, and to individuals taking Disulfiram or consuming alcohol during treatment.

Use Restrictions and Caution

Use is restricted and requires caution in populations with specific conditions, including those with severe hepatic impairment, active Central Nervous System (CNS) disease, or a history of blood dyscrasias, where close monitoring is necessary. For these groups, use is conditional on a careful risk assessment.

Age and Reproductive Status

The drug is generally not recommended during the first trimester of pregnancy for non-life-threatening infections. Following a single high dose, the official labeling requires the interruption of breastfeeding for a defined period to minimize infant exposure. Newborns and older adults require careful supervision due to altered drug clearance, which may necessitate monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies several clinically significant interaction patterns for Zol (Metronidazole), classifying some combinations as strictly contraindicated due to severe reaction risk.

Documented Prohibitions and Timing Rules

Co-administration with Disulfiram is formally contraindicated due to the risk of psychotic reactions; a mandatory separation period requires Zol not be administered if Disulfiram was taken within the last two weeks. The consumption of alcohol (Ethanol) and Propylene Glycol-containing products is also prohibited during therapy and for at least 3 days after the final dose due to the risk of a severe Disulfiram-like reaction (flushing, headache).

Pharmacokinetic and Exposure Modifications

Zol is documented to potentiate the effect of Warfarin and other oral anticoagulants, leading to a prolongation of Prothrombin Time and increased bleeding risk. Co-administration may also significantly alter plasma concentrations of other medicines: Zol increases the systemic exposure of Busulfan (raising toxicity risk) and Lithium (leading to potential retention). Conversely, drugs like Phenobarbital and Phenytoin are documented to accelerate the elimination of Zol, resulting in reduced Zol plasma levels. Cimetidine decreases Zol clearance, increasing Zol exposure.

Population and General Interaction Notes

In patients with hepatic impairment, Zol is officially documented to undergo significant accumulation, which is a population-specific consideration for interaction management. Use with other drugs that prolong the QT interval carries a documented risk of additive pharmacodynamic effects.

Mechanism of Action

Metronidazole operates through a chemical process that targets susceptible anaerobic organisms, relying on an environment low in oxygen for activation.


Reductive Activation and Functional Selectivity

The mechanism begins with the drug's reductive activation, a process where the inert Metronidazole molecule acts as an electron acceptor. This activation is performed by specific low redox-potential electron-transport proteins, such as ferredoxin, found exclusively within the target pathogens (anaerobic bacteria and protozoa). This dependency on the anaerobic environment ensures the drug's mechanism is functionally selective, meaning its activation is biochemically constrained to the intracellular environment of the target pathogen and does not readily activate in aerobic host cells.


Irreversible Microbial DNA Disruption

Once activated, the Metronidazole molecule transforms into a highly reactive nitro-free radical. This radical immediately initiates a mechanistic cascade by attacking and damaging the microbial DNA, causing strand breaks and inhibiting DNA synthesis and repair. This irreversible genetic disruption leads directly to the bactericidal/antiprotozoal physiological effect—the termination of the pathogen's viability and cell death.

Dosage and Administration Information

How Zol is Used

Zol (Metronidazole) is administered via various routes to suit the infection's location and severity. The primary methods include oral administration (using standard or extended-release tablets and suspensions) for systemic therapy, and intravenous (IV) infusion, which is typically reserved for severe cases or when oral intake is not possible. Localized use is achieved through topical preparations, or sometimes rectal administration in post-operative settings.

Dosing regimens are established based on the type of infection. For systemic maintenance, doses are generally fixed at 7.5 mg/kg or 500 mg to 750 mg per administration, with a maximum daily intake of 4 g. These doses are commonly scheduled for administration every 6 or 8 hours, though specific indications may require a single, high 2 g dose. The typical treatment course for established infections lasts between 7 and 10 days.

Administration conditions are strictly tied to the formulation. Standard oral forms can be taken independent of meals, while the extended-release tablets must be taken on an empty stomach (e.g., at least one hour before or two hours after eating). Furthermore, the IV solution requires neutralization with a suitable agent immediately prior to being infused. Dosage adjustments are mandatory for patients with severe hepatic impairment, but no routine change is needed for renal impairment, although re-administration is required following hemodialysis.

Recent Clinical Evidence

Research evidence / Overview of studies

Study 1: Examining the Drug’s Initial Impact

Research has examined whether the combination treatment was studied for the presence of measured symptom changes over time for moderate to severe pain. The study protocol involved participants receiving the quantity specified in the study protocol, and researchers tracked changes in quality of life. The trial included a comparison group receiving an older formulation. Researchers examined inflammation markers as a point of interest.


Study 2: Long-Term Findings

A three-year follow-up evaluated the drug’s use over an extended period and examined whether it was associated with changes in pain and stiffness, documenting symptom measurements taken over the full study duration. Researchers analyzed collected data regarding joint mobility. Trial eligibility criteria excluded certain pre-existing health conditions. The researchers investigated the results when the treatment was given alongside a structured regimen.


Study 3: Exploring Other Conditions

Though not yet approved, studies explored whether the medication examined effects in participants reporting chronic headaches, measuring the magnitude of the observed effect.

Frequently Asked Questions (FAQ)

Common questions about Zol (FAQ)


Q: Why do doctors prescribe Zol?

Zol (Metronidazole) is an anti-infective agent prescribed to treat a range of specific illnesses. These include various bacterial infections—such as intra-abdominal, gynecologic, and skin infections—that thrive in low-oxygen environments.

Official documents also indicate its use for treating certain parasitic illnesses like trichomoniasis and amebiasis.


Q: What happens if I miss a dose of Zol?

Regulatory information advises that a missed dose may be taken as soon as possible. However, the instructions for missed doses may vary depending on the specific dosing schedule and formulation.

Official patient information should be consulted for precise guidance.


Q: What is the typical duration of treatment with Zol?

The duration of treatment with Zol varies based on the specific infection being addressed. For many established bacterial infections, treatment commonly lasts between 7 and 10 days.

Other indications, such as certain parasitic infections, may have a shorter or slightly different course based on regulatory labeling.


Q: Is Zol safe to use if I have liver problems?

Official product information notes that patients with severe hepatic impairment (serious liver problems) may need a reduced dose and require monitoring for potential adverse events. For less severe forms of liver impairment, careful supervision by a healthcare professional is often warranted.


Q: How can I tell the difference between a minor side effect and a serious one from Zol?

Serious effects are described as those requiring immediate medical attention, such as signs of an allergic reaction or new neurological signs described in the labeling (e.g., confusion, seizures, or problems with coordination).

Common side effects, like a headache or nausea, are generally considered less serious.


Q: Is Zol considered an antibiotic?

Yes, Zol is recognized in official documents as both a nitroimidazole antibiotic and an antiprotozoal agent. This classification indicates the drug is effective against both susceptible anaerobic bacteria and specific types of parasitic organisms.


Q: Does Zol cause weight gain or weight loss?

Official reports indicate that weight loss has been reported as a less common side effect associated with the use of metronidazole. Weight gain is not frequently listed among the known side effects in the regulatory documentation.


Q: Are headaches a common side effect of Zol?

Yes, based on official reporting, headache is listed as a very common side effect of oral Metronidazole. This is one of the most frequently reported non-serious effects in the regulatory labeling.


Q: Can Zol make me feel tired or drowsy?

Dizziness or lightheadedness are more commonly reported side effects associated with the use of this drug. While somnolence (drowsiness) has been reported, it is typically classified as a rare side effect in official documents.


Q: Does Zol interact with vitamins or supplements?

Official interaction checkers do not generally show specific conflicts between metronidazole and common daily vitamins.

However, because interactions are always possible, patients are officially advised to inform their healthcare provider about all medicines and any supplements being taken.


Q: Is Zol safe to use if I have kidney disease?

Regulatory information states that patients with end-stage renal disease may clear metronidazole and its breakdown products slowly. Due to this potential for accumulation, monitoring for potential adverse events is recommended for these patients.


Q: Can children or teenagers take Zol?

Use in the pediatric population requires careful consideration, and the established indications vary by age. Official dosing instructions based on body weight are available for some conditions, and use in teenage females for specific conditions should not occur prior to the start of menstruation.


Q: Is it safe to drive after taking Zol?

Zol (Metronidazole) has been associated with Central Nervous System (CNS) effects, which may include dizziness, problems with coordination, or confusion.

If a patient experiences any abnormal neurologic signs while using the medication, prompt medical evaluation is advised.


Q: How long does Zol stay in your system?

The time it takes for Zol to fully leave the system is reflected in the official warnings about alcohol consumption. Regulatory documents advise waiting for at least 3 days (72 hours) after the final dose before drinking, as this is the recommended period for the drug’s effects and the risk of interaction to wear off.


Q: Is Zol a controlled substance?

No, Zol (Metronidazole) is a highly specialized, prescription-only drug. However, it is not classified as a controlled substance under the regulatory scheduling system in the US.


Q: Can Zol be used during pregnancy?

Official documents generally state that use is contraindicated or not recommended during the first trimester of pregnancy for non-life-threatening infections.

In the second and third trimesters, use is typically reserved for situations where the potential benefit is determined to outweigh the potential risk.


Q: Is Zol safe to use while breastfeeding?

Because Zol can pass into breast milk, some regulatory authorities advise against breastfeeding while taking metronidazole. Additionally, official labeling may require the interruption of breastfeeding for a defined period following a single high dose of the medication.


Q: Why are there different strengths of Zol?

Different strengths (e.g., 250 mg and 500 mg tablets) exist to achieve specific target plasma concentrations in the body. These concentrations are required to achieve the established therapeutic levels against the various susceptible organisms that the medicine is approved to treat.


Q: Is Zol known to interact with alcohol?

Yes, Zol (Metronidazole) is strictly contraindicated with alcohol. The official warning states that combining the medication with alcohol is associated with a severe Disulfiram-like reaction, which can cause unpleasant symptoms like severe nausea, vomiting, and flushing.


Q: What is the 'on-label' use for Zol?

The official 'on-label' uses are those approved by regulatory bodies. Zol is indicated for treating specific serious infections caused by susceptible anaerobic bacteria, including infections in the intra-abdominal, gynecologic, skin, and central nervous system areas, as well as trichomoniasis and amebiasis.


Q: Is Zol known to cause mood changes?

Rare psychiatric side effects have been reported in association with metronidazole use. These have included reports of depression, confusional states, and more serious, though rare, psychotic disorders.


Q: Is Zol approved in countries outside of the US?

Yes, the drug is widely recognized and used internationally. Zol (Metronidazole) is listed by the World Health Organization (WHO) as an Essential Medicine and is approved and available as a prescription-only drug in many other countries, including Canada and the UK.


Q: Is there a generic version of Zol available?

Yes, the active ingredient in Zol is Metronidazole, which is widely available as an authorized generic medication.


Q: Does Zol cause stomach upset?

Gastrointestinal issues are listed among the common side effects of Zol. These may include nausea, vomiting, diarrhea, constipation, and stomach cramps.


Q: Can Zol affect my sleep?

Trouble sleeping, or insomnia, is listed among the less common side effects reported in official documents for metronidazole.


Q: How often are side effects reported for Zol?

Official reporting provides general frequency data for common side effects. For instance, headache is reported as a very common side effect, seen in up to 18% of patients in some studies. Other effects are generally classified as rare or very rare.


Q: Is Zol a drug that requires blood tests?

Total and differential leukocyte counts (blood tests) are recommended before and after therapy for certain patients, according to official precautions.

Official precautions indicate that this type of monitoring is suggested for individuals with a history of blood disorders or those receiving repeated courses of treatment.


Q: Where can I find official information about Zol?

You can find authoritative, regulatory information about the drug on official government-run websites. These include the US DailyMed/FDA labeling site or the NIH MedlinePlus drug information resource.


Q: Are there any long-term effects of taking Zol?

Long-term use or the administration of high doses has been associated with reports of serious, generally reversible, Central Nervous System effects.

These include serious Central Nervous System effects, such as a risk of encephalopathy or nerve damage (peripheral neuropathy), which are often reported as generally reversible.


Q: What did the main clinical trials of Zol investigate?

The main clinical trials investigated and supported the drug's use for its approved indications. This research focused on treating specific infections, including trichomoniasis, amebiasis, and serious anaerobic bacterial infections across various body sites.


Q: Is Zol a blood thinner?

No, Zol (Metronidazole) is classified as an antibiotic and antiprotozoal agent. However, it is documented to significantly potentiate the effect of Warfarin and other oral anticoagulants (blood thinners), which can increase the risk of bleeding.

How should Zol be stored and disposed of?

Official Storage and Disposal Requirements

Metronidazole (Zol) must be stored and discarded according to specific conditions defined by regulatory labeling to maintain product stability and safety.

Requirement Area Official Conditions
Temperature Control Store tablets at Controlled Room Temperature (20 to 25 C), protecting the medication from excessive heat. It must be kept from freezing.
Handling & Protection Keep the product in a well-closed container, away from direct light and moisture.
Child Safety The medication must be kept out of the reach of children to prevent accidental ingestion.
Disposal Instructions Unused or expired metronidazole should preferably be disposed of through a drug take-back program. Otherwise, it should be removed from its original container, mixed with an undesirable substance (e.g., coffee grounds), sealed in a bag or container, and discarded in the household trash. Do not flush down the toilet unless directed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zol found in:

A-Z Index: